Fennec Pharmaceuticals Inc.

NASDAQ:FENC

Biotechnology

Healthcare
$13.33 -1.34%

-$0.12 today

Market cap
$470.62M
Beta
1.08
P/E (TTM)
-36.3
EPS (TTM)
-$0.24
52W Low $5.65High $10.45

Volume 0.59M

Average 0.26M

Returns on capital

Fennec Pharmaceuticals Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-27.8%

avg 44.3%

ROIC

-10.7%

avg -84.2%

ROA

-13.9%

avg -53.9%

Analysis

ROIC is currently the strongest return metric at -10.7% versus its period average of -84.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jeffrey S. Hackman

Chief Executive Officer & DirectorUSD 632.18K6370.84K0.25%

Robert C. Andrade

Chief Financial OfficerUSD 552.65K51——

Pierre S. Sayad

Chief Medical OfficerUSD 464.08K———

Lei Fang

President of Pharstat Inc————

Mark Gowland

Controller————

Terry Evans

Chief Commercial Officer————

Christiana Cioffi

Chief Strategy Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 31, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

16

$9.79M

Net Transaction Value

−$9.79M

Net selling

Most Active

Raykov Rosty

10 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 15, 26

Brughera Marco Maria

Direct

Sell$160K
Sep 1, 26

Raykov Rosty

Direct

Sell$121.1K
Aug 31, 26

Sayad Pierre Sargis

Direct

Sell$146.2K
Aug 27, 26

Andrade Robert

Direct

Sell$883.5K
Aug 3, 26

Raykov Rosty

Direct

Sell$95.8K
Jul 1, 26

Raykov Rosty

Direct

Sell$99.9K
Jun 1, 26

Raykov Rosty

Direct

Sell$93.8K
May 11, 26

RALLIS CHRIS A

Direct

Sell$58.8K
May 1, 26

Raykov Rosty

Direct

Sell$69.8K
Apr 1, 26

Raykov Rosty

Direct

Sell$69.1K

1–10 of 16

Summary

Insiders reported 0 buys worth $0.00 and 16 sells worth $9.79M over the last 12 months. That adds up to net selling of $9.79M. Raykov Rosty was the most active insider with 10 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+207.5%
+40.1% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +207.5% over three years. Forward estimates point to Revenue at +40.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Fennec Pharmaceuticals Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about FENC's management, answered from reported figures.

Who manages FENC?

Fennec Pharmaceuticals Inc. (FENC) lists 7 active executives. The top listed executive is Pierre S. Sayad, Chief Medical Officer.

Are FENC insiders buying or selling?

Recent insider activity shows net selling of $6.87M.